Quick Answer
Ernexa Therapeutics Inc. reported Cash And Cash Equivalents At Carrying Value of $1.73 million for the year ending 2024.
- Ernexa Therapeutics Inc. showed a decrease of -77.2% in Cash And Cash Equivalents At Carrying Value from 2023 to 2024.
- This data is from Ernexa Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2025.
- XBRL data for this metric is available from 2009 to 2024 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 16 years of available data (2009 to 2024), Ernexa Therapeutics Inc.'s Cash And Cash Equivalents At Carrying Value has declined by 52.5%.
- Historical annual values: Fiscal year 2024: $1.73 million | Fiscal year 2023: $7.58 million | Fiscal year 2022: $11.45 million | Fiscal year 2021: $16.99 million | Fiscal year 2020: $777.0 thousand | Fiscal year 2019: $3.21 million | Fiscal year 2018: $2.54 million | Fiscal year 2017: $3.38 million | Fiscal year 2016: $5.69 million | Fiscal year 2015: $3.22 million | Fiscal year 2014: $7.19 million | Fiscal year 2013: $5.46 million | Fiscal year 2012: $2.72 million | Fiscal year 2011: $1.37 million | Fiscal year 2010: $3.91 million | Fiscal year 2009: $3.64 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: